Akèy › Kansè ovè › Kalifòni › San Francisco
Etid klinik pou Kansè ovè nan San Francisco, CA
19 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote San Francisco (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
Ap rekrite
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- California Pacific Medical Center - Van Ness Campus /ID# 275329, San Francisco
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ap rekriteFaz 3
- UCSF Medical Center at Mission Bay ( Site 0013), San Francisco
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Ap rekriteFaz 1
- University of California, San Francisco
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- UCSF Medical Center-Mission Bay, San Francisco
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Ap rekriteFaz 3
- Site 0115, San Francisco
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ap rekrite
- Kaiser Permanente-San Francisco, San Francisco
- UCSF Medical Center-Mission Bay, San Francisco
A Study of DM002 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of California San Francisco Cancer Center, San Francisco
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ap rekriteFaz 2
- 014, San Francisco
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ap rekriteFaz 2
- University of California San Francisco, San Francisco
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- UCSF Medical Center at Mission Bay, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- University of California San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, San Francisco
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
Lòt etid nan San Francisco
- Kansè pwostat45 etid
- Kansè nan tete43 etid
- Kansè Poumon ki pa ti selil36 etid
- Kansè (tout kalite)35 etid
- Ensifizyans kadyak29 etid
- Kansè Metastatik28 etid
- Kansè poumon22 etid
- Melanom22 etid
- Kansè pankreyas20 etid
- Kansè kolorektal18 etid
- Maladi kadyovaskilè18 etid
- Gliyoblastòm17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.